Proteasome Inhibitors Therapeutics Analysis, Clinical Trials, Results and Developments
The study analyzed that the proteasome inhibitor therapeutics pipeline comprises approximately 20 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/proteasome-inhibitors-therapeutics/report-sample
Protein degradation and synthesis in the body are regulated by proteasome activity of multimeric protease complex. The protein conjugated to multiple units of polypeptide proteasome ubiquitin are degraded by proteasome. The accumulation of ubiquitinated proteins can lead to apoptosis. The proteasome units include 20S core catalytic complex and 19S regulatory subunits at each end, forming 26S complex. Ubiquitin is 76 amino acids complex and covalently linked to proteins by an enzymatic reaction.
Viteava Pharmaceuticals Inc. (Viteava) announced the execution of a sponsored research agreement with McGill University relating to novel analogs and derivatives of the green tea flavonoid, (-) epigallocatechin-3-gallate (EGCG).
Browse report at: https://www.psmarketresearch.com/market-analysis/proteasome-inhibitors-therapeutics
Some of the key players developing drugs as proteasome inhibitors include Triphase Accelerator Corporation, Cantex Pharmaceuticals, Inc., Accuitis, Inc. and others.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
